Novel approaches to targeting neuropeptide systems

Trends in Pharmacological Sciences

Volumn 21, Issue 12, 2000, Pages 475-483

  Roques, Bernard P ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; NEUROPEPTIDE; TACHYKININ RECEPTOR ANTAGONIST;

DRUG USE; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANXIETY; DEPRESSION; DOPAMINE; ENKEPHALINS; ENZYME INHIBITORS; HUMANS; METALLOENDOPEPTIDASES; MICE; NEUROPEPTIDES; PAIN; PROTEASE INHIBITORS; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, OPIOID; REWARD; SINCALIDE; SUBSTANCE-RELATED DISORDERS;

EID: 0034387741     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01571-6     Document Type: Review

References (71)

1. Distinct mechanism for antidepressant activity by blockade of central substance P receptors
2. Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology
3. Recent advances in molecular recognition and signal transduction of active peptides: Receptors for opioid peptides
4. International union of pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors
5. Aminopeptidase A inhibitors as potential central antihypertensive agents
6. Evolutionary families of metallopeptidases
7. Haemodynamic brain response to acute pain in humans: Sensory and attentional networks
8. Changes in central opioid receptor binding in relation to inflammation and pain in patients with rheumatoid arthritis
9. Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin
10. Opioid-related changes in nociceptive threshold and in tissue levels of enkephalins after target disruption of the gene for neutral endopeptidase (EC 3.4.24.11) in mice
11. Endogenous opioids implicated in the dynamics of experimental drug addiction. An in vivo autoradiographic analysis
12. Genotypic differences in mesolimbic enkephalin gene expression in DBA/2J and C57BL/6J inbred mice
13. Region-specific up-regulation of opioid receptor binding in enkephalin knockout mice
14. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene
15. Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia
16. New research approach to the treatment of pain: The development of complete inhibitors of the enkephalin catabolism
17. Phosphorus-containing peptides as mixed inhibitors of endopeptidase 3.4.24.15 and 3.4.24.16: Effect on neurotensin degradation in vitro and in vivo
18. Purification of substance P endopeptidase (SPE) activity in human spinal cord and subsequent comparative studies with SPE in cerebrospinal fluid and with chymotrypsin
19. Neutral endopeptidase modulation of septik shock
20. Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P
21. Targeted deletion of the neutral endopeptidase gene alters ventilatory responses to acute hypoxia in mice
22. Aminopeptidase A involved in the inactivation of endogenous CCK-8: A microdialysis study
23. Characterization and inhibition of a cholecystokinin-inactivating serine peptidase
24. Evidence for a high-affinity uptake system for cholecystokinin octapeptide (CCK-8) in rat cortical synaptosomes
25. Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety
26. CCK in anxiety and cognitive processes
27. Interactions between cholecystokinin and other neurotransmitter systems
28. Decrease in short-term memory function induced by CCK-4 in healthy volunteers
29. Cholecystokinin and psychiatric disorders: Role in aetiology and potential of receptor antagonists in therapy
30. Dual modulation of dopamine release from anterior nucleus accumbens through cholecystokinin-B receptor-subsites
31. Analysis of variation in L-365,260 competition curves in radioligand binding assays
32. Opposite effects of CCK-B agonists in grooming behavior of rats, further evidence for two CCK-B subsites
33. The endocannabinoid system as a target for therapeutic drugs
34. Reversal of dopamine D2-receptor responses by an anandamide transport inhibitor
35. The dual peptidase inhibitor RB 101 induces a long-lasting increase in the extracellular level of Met-enkephalin-like material in the nucleus accumbens of freely moving rats
36. Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: Synthesis, biological properties, and antinociceptive activities
37. 3H]-diprenorphine binding
38. Pharmacological studies of nociceptive systems using the c-Fos immunohistochemical technique: An indicator of noxiously activated spinal neurons
39. Spinal cord pharmacology of pain
40. Effects of enkephalin-catabolizing enzymes inhibitors RB 101 and kelatorphan on respiration
41. Analgesic doses of the enkephalin degrading enzyme inhibitor RB 120 do not have discriminative stimulus properties
42. Potentiation of enkephalin action by peptidase inhibitors in rat locus coeruleus in vitro
43. Functional dissociation of μ-opioid receptor signaling and endocytosis: Implications for the biology of opiate tolerance and addiction
44. Effect of inhibiting enkephalin catabolism in the VTA on motor activity and extracellular dopamine
45. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and D1 dopamine receptor stimulation
46. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds
47. Mice deficient for δ-opioid and μ-opioid receptors exhibit opposing alterations of emotional responses
48. Opioid δ agonists and endogenous enkephalins induce different emotional reactivity than μ agonists after injection in the rat ventral tegmental area
49. Endogenous opioid system and alcohol addiction
50. Role of delta opioid receptors in the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys
51. Drug abuse: Hedonic homeostatic dysregulation
52. Drug addiction as dopamine-dependent associative learning disorder
53. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors
54. Alcohol preference and sensitivity are markedly reduced in mice lacking dopamine D2 receptors
55. The dopamine hypothesis of reward: Past and current status
56. 1 receptor knockout mice
57. 1 receptor knock-out mice
58. Rewarding effects of opiates are absent in mice lacking the receptor for substance P
59. Altered nociception, analgesia and agression in mice lacking the receptor for substance P
60. Drug addiction: The yin and the yang of hedonic homeostasis
61. Cholecystokinin/opioid interactions
62. Opposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalin antidepressant-like effects
63. δ2-Opioid receptor mediation of morphine-induced CCK release in the frontal cortex of the freely moving rat
64. The attenuation of morphine-conditioned place preference following chronic mild stress is reversed by a CCK-B receptor antagonist
65. The CCK-B antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats
66. Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism
67. Cholecystokinin in CSF from depressed patients: Possible relations to severity of depression and suicidal behaviour
68. Social interaction increases the extracellular levels of Met-enkephalin in the nucleus accumbens of control but not of chronic mild stressed rats
69. Cholecystokinin B receptor antagonists enhance the locomotor response to the N-methyl-D-aspartate antagonists, phencyclidine and dizocilpine maleate
70. The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK-8 in the posterior nucleus accumbens
71. Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation